Bristol Myers Squibb: Bargain Buy or Value Trap?
The healthcare stock trades at a forward earnings multiple of just nine, and its growth rate has been in the low single digits this year.
Bristol Myers Squibb (BMY) is a prominent name in the healthcare industry, boasting a market capitalization of approximately $125 billion. However, over the past five years, the stock has only delivered returns of 6%, faring poorly compared to the S&P 500's impressive 70% growth over the same period. Bristol Myers has faced skepticism due to uncertainty surrounding its future growth, leading to a low valuation and an attractive yield.
The management has categorized its products into legacy and growth portfolios to demonstrate that the company is not in as dire a situation as initially perceived.
During the first half of the year, the legacy portfolio saw a 6% revenue decline, excluding foreign exchange effects, while the growth portfolio experienced a 12% organic growth rate. Despite this, the growth portfolio now surpasses the legacy portfolio in terms of revenue, generating $13.8 billion in sales compared to $10.7 billion.
The company's top-line growth has been modest, with an organic growth rate of just 3% over this period. However, the performance of the growth portfolio has boosted investor confidence, resulting in a nearly 14% increase in Bristol Myers' stock price this year, slightly surpassing the S&P 500's 12% growth.
While Bristol Myers stock has outperformed the market this year, its valuation remains remarkably low, trading at just nine times its estimated future earnings, which is significantly lower than the S&P 500's average multiple of 19. The company has faced challenges due to patent expirations, common among drug manufacturers, but its growth-focused portfolio has allowed it to perform relatively well given the circumstances.
The stock's low valuation provides investors with a substantial margin of safety, and its high-yielding dividend, currently at 4.1% with a sustainable payout ratio of around 55%, adds to its appeal. Bristol Myers is, therefore, a stock that can be considered a bargain, and it is an excellent choice for long-term investors looking to purchase during this opportune moment.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
